UK Markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.65000.0000 (0.00%)
At close: 03:16PM EDT
Full screen
Loading interactive chart…
  • Business Wire

    Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

    LONDON, September 29, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced preliminary results from the single dose component of the GEMINI II phase 1 study of SLN124, a siRNA targeting the TMPRSS6 gene, in 24 adults with non-transfusion dependent thalassemia.

  • Business Wire

    Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference

    LONDON, September 27, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside chat at the Chardan Genetic Medicines Conference on Tuesday, October 4th at 3:45 p.m. ET in New York.

  • Business Wire

    Silence Therapeutics to Participate in September Investment Conferences

    LONDON, September 08, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that company management will participate in the following conferences: